CTLA4-Ig: Phase I interim data

In a U.S., open-label, dose-escalating Phase I study in patients with relapsing-remitting MS, a single dose of CTLA4-Ig at 2mg/kg or 10mg/kg was safe. Patients received a single dose of CTLA4-Ig at 2,...